Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SF3B3 | Q15393 | 10/20 | 0.76 |
| ▸ | HMGCR | P04035 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905749 | 1.00 | SF3B3 (0.76) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30311586 | 1.00 | SF3B3 (0.76) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12877318 | 1.00 | SF3B3 (0.76) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14539614 | 1.00 | SF3B3 (0.76) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1505026 | 0.95 | SF3B3 (0.70) | SF3B3HMGCR | |
| SCHEMBL3626171 | 0.95 | SF3B3 (0.70) | SF3B3HMGCR | |
| SCHEMBL1504956 | 0.94 | SF3B3 (0.69) | SF3B3HMGCR | |
| SCHEMBL13748880 | 0.94 | SF3B3 (0.71) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13714905 | 0.94 | SF3B3 (0.69) | SF3B3 | |
| SCHEMBL3619306 | 0.94 | SF3B3 (0.66) | SF3B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193715-B2 | Regulation of cholesterol homeostasis | UNIVERSITY OF NOTRE DAM DU LAC (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150038566-A1 | REGULATION OF CHOLESTEROL HOMEOSTASIS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-02-05 | — | — | US | disclosed |
| US-8865761-B1 | Regulation of cholesterol homeostasis | THE UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140275010-A1 | QUATERNARY SALTS | ZHENG GUO ZHU (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275010-A1 | QUATERNARY SALTS | ZHENG GUO ZHU (US) | 2014-09-18 | — | — | US | disclosed |
| US-7884128-B2 | reacting 11-{[tert-butyl(dimethyl)silyl]oxy}-7-[(E)-2-formyl-1-methyleth-1-en-1-yl]-6,13a-dimethyl-2-phenyl-3a,6,7,10,11,12,13,13a-octahydro-9H-[1,3]dioxolo[4,5-f]oxacyclododecin-9-one with 2-methyl-3-[(1-phenyl-1H-tetrazol-5-yl)sulfonyl]propyl}oxiran-2-yl)pentane-3-ol, to form pladienolide analogues | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884128-B2 | reacting 11-{[tert-butyl(dimethyl)silyl]oxy}-7-[(E)-2-formyl-1-methyleth-1-en-1-yl]-6,13a-dimethyl-2-phenyl-3a,6,7,10,11,12,13,13a-octahydro-9H-[1,3]dioxolo[4,5-f]oxacyclododecin-9-one with 2-methyl-3-[(1-phenyl-1H-tetrazol-5-yl)sulfonyl]propyl}oxiran-2-yl)pentane-3-ol, to form pladienolide analogues | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7816401-B2 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7816401-B2 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | KANADA REGINA MIKIE | 2010-08-12 | — | — | US | disclosed |
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | KANADA REGINA MIKIE | 2010-08-12 | — | — | US | disclosed |
| US-20080021226-A1 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. | 2008-01-24 | — | — | US | disclosed |
| US-20080021226-A1 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038566-A1 | REGULATION OF CHOLESTEROL HOMEOSTASIS | NPC1L1, NPC1, CETP | SF3B3 1703/4885HMGCR 26/4885MEN1 2361/4885 |
| US-20140275010-A1 | QUATERNARY SALTS | TP53, VHL, SF3B5 | SF3B3 16/4885HMGCR 2013/4885MEN1 383/4885 |
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | CYP8B1, PLA2G2D, HPD | SF3B3 861/4885HMGCR 505/4885MEN1 3007/4885 |
| US-20080021226-A1 | Process for total synthesis of pladienolide B and pladienolide D | TPD52L2, CYP8B1, HPD | SF3B3 1988/4885HMGCR 347/4885MEN1 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.